HIV testing and burden of HIV infection in black cancer patients in Johannesburg, South Africa: a cross-sectional study. by Sengayi, Mazvita et al.
BMC Cancer
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
HIV testing and burden of HIV infection in black cancer patients in Johannesburg,
South Africa: a cross-sectional study
BMC Cancer Sample
doi:10.1186/s12885-015-1171-7
Mazvita Sengayi (mazvita.sengayi@nhls.ac.za)
Chantal Babb (chantal.babb@nhls.ac.za)
Matthias Egger (egger@ispm.unibe.ch)
Margaret I Urban (margurban@gmail.com)
Sample
 
ISSN 1471-2407
Article type Research article
Submission date 15 August 2014
Acceptance date 6 March 2015
Article URL http://dx.doi.org/10.1186/s12885-015-1171-7
 
 
For information about publishing your research in BioMed Central journals, go to
http://www.biomedcentral.com/info/authors/
 
© 2015 Sengayi et al.; licensee BioMed Central.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
 (2015) 15:144 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
70
96
4 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
HIV testing and burden of HIV infection in black 
cancer patients in Johannesburg, South Africa: a 
cross-sectional study 
Mazvita Sengayi1,2,* 
* Corresponding author 
Email: mazvita.sengayi@nhls.ac.za 
Chantal Babb1,3 
Email: chantal.babb@nhls.ac.za 
Matthias Egger4,5 
Email: egger@ispm.unibe.ch 
Margaret I Urban1,3 
Email: margurban@gmail.com 
1 NHLS/MRC Cancer Epidemiology Research Group, National Cancer Registry, 
National Health Laboratory Service, Johannesburg, South Africa 
2 Graduate School for Cellular and Biomedical Sciences, University of Bern, 
Bern, Switzerland 
3 School of Pathology, Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, South Africa 
4 Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, 
Switzerland 
5 Centre for Infectious Disease Epidemiology and Research (CIDER), School of 
Public Health and Family Medicine, University of Cape Town, Cape Town, 
South Africa 
Abstract 
Background 
HIV infection is a known risk factor for cancer but little is known about HIV testing patterns 
and the burden of HIV infection in cancer patients. We did a cross-sectional analysis to 
identify predictors of prior HIV testing and to quantify the burden of HIV in black cancer 
patients in Johannesburg, South Africa. 
Methods 
The Johannesburg Cancer Case–control Study (JCCCS) recruits newly-diagnosed black 
cancer patients attending public referral hospitals for oncology and radiation therapy in 
Johannesburg . All adult cancer patients enrolled into the JCCCS from November 2004 to 
December 2009 and interviewed on previous HIV testing were included in the analysis. 
Patients were independently tested for HIV-1 using a single ELISA test . The prevalence of 
prior HIV testing, of HIV infection and of undiagnosed HIV infection was calculated. 
Multivariate logistic regression models were fitted to identify factors associated with prior 
HIV testing. 
Results 
A total of 5436 cancer patients were tested for HIV of whom 1833[33.7% (95% CI=32.5-
35.0)] were HIV-positive. Three-quarters of patients (4092 patients) had ever been tested for 
HIV. The total prevalence of undiagnosed HIV infection was 11.5%(10.7-12.4) with 34% 
(32.0–36.3) of the 1833 patients who tested HIV-positive unaware of their infection. Men 
>49years [OR 0.49(0.39–0.63)] and those residing in rural areas [OR 0.61(0.39–0.97)] were 
less likely to have been previously tested for HIV. Men with at least a secondary education 
[OR 1.79(1.11–2.90)] and those interviewed in recent years [OR 4.13(2.62 – 6.52)] were 
likely to have prior testing. Women >49years [OR 0.33(0.27–0.41)] were less likely to have 
been previously tested for HIV. In women, having children <5years [OR 2.59(2.04–3.29)], 
hormonal contraceptive use [OR 1.33(1.09–1.62)], having at least a secondary education 
[OR:2.08(1.45–2.97)] and recent year of interview [OR 6.04(4.45–8.2)] were independently 
associated with previous HIV testing. 
Conclusions 
In a study of newly diagnosed black cancer patients in Johannesburg, over a third of HIV-
positive patients were unaware of their HIV status. In South Africa black cancer patients 
should be targeted for opt-out HIV testing. 
Keywords 
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Background 
HIV-1 infection was classified as a human carcinogen by the International Agency for 
Research on Cancer (IARC) in 1996 [1]. South Africa has the largest HIV burden worldwide 
with an estimated 6.4 million people living with HIV in mid-2012 [2]. Black Africans are 
disproportionately affected by the epidemic compared to other population groups. According 
to the South African 2012 HIV prevalence survey, prevalence in the reproductive age group 
(15–49 years) was 22.7%, 0.6%, 4.6% and 1.0% in blacks, whites, coloureds (mixed race) 
and Indians/Asians respectively [2]. In order to understand the burden and spectrum of HIV-
related cancers, it is essential to identify people with HIV and cancer co-morbidity. Strategies 
to identify patients with both HIV infection and cancer include screening for cancers at HIV 
clinics [3] and testing cancer patients for HIV [4,5]. 
The 2010 South African HIV counselling and testing guidelines recommend provider-
initiated HIV testing and counselling (PITC) for all patients attending healthcare facilities [6]. 
PITC is defined as “HIV testing and counselling that is initiated and offered by health-care 
providers to all clients attending health-care facilities as a standard component of care” [6]. 
The World Health Organization recommends an ‘opt-out’ approach to PITC in generalised 
HIV epidemics (i.e. where antenatal HIV prevalence exceeds 1%), which not only obliges 
health care workers to offer HIV testing to every patient, but also incorporates the informed 
right of the patient to decline the recommendation of an HIV test [7]. In this paper, PITC and 
opt-out HIV testing will be used synonymously. 
PITC has been shown to increase HIV testing almost three-fold in primary care clinics in 
Gauteng province, South Africa, compared to referral to on-site voluntary counselling and 
testing services [8]. Challenges to widespread opt-out HIV testing include overburdening a 
strained healthcare system, ensuring confidentiality in shared consulting rooms, on-going 
staff training and preventing test kit stock-outs [8]. Therefore there is still a role for targeted 
PITC among high risk groups, including in antenatal and post-natal clinics, tuberculosis 
treatment facilities, family planning clinics, sexually transmitted infections clinics and post-
exposure prophylaxis centres [6]. Indeed, a recent systematic review of studies in antenatal 
care concluded that the adoption of PITC can greatly increase testing uptake [9]. 
HIV testing patterns in the general South African population have been studied: a 
representative survey in 2005 found that being female, employed, aged 25–34 years, having a 
higher education and residing in an urban area were all associated with greater knowledge of 
HIV status [10]. Women have consistently been found to be more likely to know their HIV 
status than men [2,10-15], even after accounting for pregnancy-related HIV testing [11]. The 
youth [14], older women [15] and older men [11,12] are less likely to be tested; the majority 
of older men who test for HIV generally do so when there is a medical indication [11]. Little 
is known about HIV testing patterns and the burden of HIV infection in cancer patients [4]. 
The aim of this study was to identify factors associated with HIV testing and to quantify the 
burden of HIV in newly diagnosed black cancer patients in Johannesburg, Gauteng province, 
South Africa. 
Methods 
Ethics statement 
The study was approved by the University of the Witwatersrand Human Research Ethics 
Committee (Medical). 
Study setting and design 
Since 1995, the Johannesburg Cancer Case–control Study (JCCCS) has recruited newly 
diagnosed self-defined black cancer patients attending public referral hospitals (Chris Hani 
Baragwanath, Hillbrow and Charlotte Maxeke Johannesburg Academic Hospital) for 
oncology and radiation therapy in the greater Johannesburg area [16]. To date, over 20 000 
black cancer patients have been interviewed, of whom the majority (over 90%) have donated 
blood specimens for evaluation of infectious and genetic risk factors for cancer and their 
interactions with socio-demographic and environmental factors collected via questionnaire. 
At the time of the current analysis, the JCCCS patient recruitment was confined to only 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) (formerly Johannesburg 
General Hospital). 
Eligibility criteria 
All patients with confirmed cancer, aged ≥ 18 years, who were enrolled into the JCCCS at 
CMJAH from November 2004 to December 2009 and who were interviewed on previous 
HIV testing, were included in this study. 
Procedures and definitions 
Trained nurse counsellors used a standard questionnaire to interview cancer patients in their 
preferred language (usually Zulu or Sotho). All patients gave written or witnessed verbal 
informed consent prior to being interviewed and having blood drawn. Patients were asked 
questions on place of birth, rural or urban residence, schooling, reproductive history, use of 
hormonal contraception, number of lifetime sexual partners, and alcohol and tobacco use. 
From November 2004, in addition to the standard questionnaire, all patients aged 55 or less 
were asked about previous HIV testing. After November 2006, all recruited patients were 
interviewed on prior HIV testing. Patients were asked the following questions to explore their 
HIV testing patterns: Have you ever been tested for HIV? Were you tested: before this illness 
/ at time of current illness only? Were you given the test results? Are you willing to disclose 
your status? If yes, are you HIV positive or negative? 
Nurse counsellors took blood samples from consenting patients at the time of interview, 
before patients had received any cancer treatment. Blood samples were collected in 10 ml 
red-top plain vacutainers. Serum separation was done by standard centrifugation, and serum 
specimens were frozen at −20 to −30°C before batching for HIV testing. Specimens were 
tested for HIV-1 using a single Vironostika (HIV Uniform II plus O) micro enzyme-linked 
immunosorbent assay (ELISA) test. Specimens with inconclusive ELISA tests were classified 
as HIV negative. All tests were done at the Serology Laboratory, Centre for HIV and STIs, 
National Institute for Communicable Diseases, Johannesburg. 
Prior HIV testing was defined as self-reported history of HIV testing before the current 
cancer illness. Awareness of HIV status was defined as self-reported HIV status consistent 
with the result of the HIV-1 ELISA test. Cancers were classified according to the 
International Classification of Diseases for Oncology Third Edition (ICD-O-3) [17]. We 
classified cervical cancer (ICD-O topography code C53), Kaposi sarcoma (ICD-O 
morphology code M91403) and non-Hodgkin lymphoma (ICD-O topography codes C82-83 
or ICD-O morphology code M9590 – 9595, M9670 – 9717 and M9820 - 9837) as AIDS-
defining cancers [18]. The majority (98.4%) of patients included in the analysis had 
verification of cancer diagnosis by histology, haematology or cytology. Coding of cancers 
was done by an experienced coder working for the JCCCS and quality controlled by one of 
the authors (MIU) who has extensive coding expertise; assistance from oncologists, 
histopathologists and / or cytologists was sought where needed. 
Statistical analyses 
We used means and proportions to describe the characteristics of newly diagnosed cancer 
patients. We determined the ten most frequent cancers in men and in women by HIV status 
and calculated the prevalence of prior HIV testing, of HIV infection and of undiagnosed HIV, 
with exact binomial 95% confidence intervals (CI). We compared age-specific HIV 
prevalence in male and female black cancer patients with HIV prevalence in black men and 
women in the South African general population, as reported in the 2008 national HIV 
prevalence survey [19]. We also calculated prevalence of HIV and undiagnosed HIV by 
cancer type (see Additional file 1: Table S6). 
We fitted logistic regression models to identify factors associated with prior HIV testing in 
black cancer patients. Separate models were calculated for men and women. The following 
variables were entered into the models: age (≤49 years, >49 years), place of residence (rural 
vs. urban), marital status (married, single, widowed, divorced), year of interview, highest 
level of education achieved (none, primary and secondary/tertiary), alcohol use (non-
drinkers, moderate drinkers and heavy/binge drinkers), smoking (non-smokers, ex-smokers, 
current light smokers and current heavy smokers), lifetime number of sexual partners (0–1, 
2–5 and 6 or more), having children under the age of five, cancer type (AIDS defining or 
other cancers), hormonal contraceptive use (ever, never) and interviewer. We had three nurse 
interviewers: interviewer 1, the most senior interviewer, was with the study during the entire 
period; interviewer 3 replaced interviewer 2 in September 2009. We classified alcohol use as 
follows: non-drinkers (<1 drink per week), moderate drinkers (1–7 drinks/week for women, 
1–14 drinks/week for men) and heavy/binge drinkers (8 or more drinks/week or 4 or more 
drinks in a single occasion for women, 15 or more drinks/week or 5 or more drinks in a single 
occasion for men) [20]. We considered that some patients may have quit smoking due to their 
illness; hence those who stopped smoking more than 5 years prior to the date of interview 
were classified as ex-smokers while those who smoked within 5 years of the date of interview 
were classified as current smokers. Current smokers were further classified into ‘light’ (1 – 
14 g/day) and ‘heavy’ (15 g/day or more) current smokers, assuming weights of 1 g per 
cigarette or hand rolled cigarette or pipe [21]. 
We added variables to multivariate models sequentially, starting with variables with the 
smallest p value in univariate analysis. Likelihood ratio tests were performed to determine 
which variables were kept in the models. The final model for men was adjusted for age, place 
of residence, highest level of education achieved, year of interview and interviewer. The final 
model for women was adjusted for age, highest level of education achieved, year of 
interview, having children under the age of five, hormonal contraceptive use and interviewer. 
Stata software (version 13, Stata Corporation, College Station, Texas, USA) was used for all 
analyses. 
Results 
Characteristics of cancer patients 
Out of the 7012 eligible patients who were approached, 270 did not participate, 1300 were 
not interviewed on HIV testing and 69 did not have HIV screening test results (Figure 1). 
Reasons for non-participation were: too sick / in pain 105 (39%), unable to communicate 56 
(21%), refused 44 (16%), left before interview 33 (12%), impaired cognitive function 28 
(10%) and other 4 (2%). The remaining study sample had 5436 patients with HIV test results. 
Two thirds of patients were female and 54% patients were 49 years old or younger (Table 1). 
The majority (89%) were urban dwellers and 58% were married or lived with their partner. 
Forty percent of patients had completed primary education or less. Fifteen percent were 
heavy/binge alcohol drinkers and 28% were current smokers. A quarter of all patients had 
had more than five sexual partners in their lifetime. Only 13% had children under the age of 
five. The majority of women (63%) had previously used hormonal contraceptives. Missing 
data were ≤2% for all variables, except for the variable “having children under 5 years”, 
where 9.3% of data were missing. 
Figure 1 Flowchart of cancer patient recruitment (2004 – 2009). 
Table 1 Characteristics of newly diagnosed black South African cancer patients (2004 – 2009) 
Characteristics N % 
Age   
≤49 years 2954 54.3 
>49 years 2482 45.7 
Mean (Standard deviation) 47.8 (12.2)  
Place of residence   
Urban 4840 89.0 
Rural 591 10.9 
Missing data 5 0.1 
Gender   
Male 1793 33.0 
Female 3643 67.0 
Marital Status   
Married/Living together 3147 57.9 
Single/Never married 680 12.5 
Widowed 737 13.6 
Separated/Divorced 863 15.9 
Missing data 9 0.2 
HIV Screening Test Result   
Negative 3603 66.3 
Positive 1833 33.7 
Level of Education   
None 549 10.1 
Primary 1641 30.2 
Secondary/Tertiary 3238 59.6 
Missing data 8 0.2 
Alcohol Use   
Non-drinkers 3253 59.8 
Moderate drinkers 1342 24.7 
Heavy/Binge drinkers 841 15.5 
Smoking   
Non-smokers 3436 63.2 
Ex-smokers 457 8.4 
Current smokers (1 – 14 g/day) 1099 20.2 
Current smokers (15+ g/day) 444 8.2 
Lifetime number of sexual partners   
0-1 585 10.8 
2-5 3401 62.6 
6+ 1343 24.7 
Missing data 107 2.0 
Having children under 5 years   
No 4233 77.9 
Yes 700 12.9 
Missing data 503 9.3 
Cancer Type   
AIDS-defining 1923 35.4 
Other cancers 3513 64.6 
Hormonal Contraceptive Use (Women Only)   
Never 1329 36.5 
Ever 2299 63.1 
Missing data 15 0.4 
Interviewer   
Interviewer 1 3161 58.2 
Interviewer 2 2074 38.1 
Interviewer 3 201 3.7 
Cancers in men and women by HIV status 
The five most common cancers in HIV-positive men were Kaposi sarcoma (KS), non-
Hodgkin lymphoma (NHL), oro-pharyngeal, lung and naso-laryngeal cancers, totalling 75% 
of all cancers (Table 2). In HIV-negative men, the top five cancers were oro-pharyngeal, 
lung, oesophageal, naso-laryngeal and stomach cancers, totalling 54% of all cancers. For 
HIV-positive women, the five most common cancers were cervical, breast, KS, NHL and 
oro-pharyngeal cancer, totalling 84% of all cancers. In HIV-negative women, the top five 
cancers were breast, cervical, oesophageal, ovarian and uterine cancer, totalling 77% of all 
cancers. 
Table 2 Ten most frequent cancers in black South African men and women by HIV status (2004 – 2009) 
HIV positive men (n = 596) HIV negative men (n = 1197) 
Kaposi sarcoma 260 (43.6) Lip, oral cavity and pharynx 216 (18.1) 
NHL 94 (15.8) Lung 167 (14.0) 
Diffuse large B cell lymphoma 54 (9.1)   
Burkitt’s lymphoma 6 (1.0) 
Other NHL 34 (5.7) 
Lip, oral cavity and pharynx 38 (6.4) Oesophagus 125 (10.4) 
Lung 34 (5.7) Nasal cavity and larynx 82 (6.9) 
Nasal cavity and larynx 21 (3.5) Stomach 54 (4.5) 
Oesophagus 19 (3.2) Colon 45 (3.8) 
Hodgkin Lymphoma 15 (2.5) Anorectal 45 (3.8) 
Liver 11 (1.9) Liver 45 (3.8) 
Stomach 9 (1.5) Pancreas 39 (3.3) 
Skin (non-melanoma, non-SCC*) 7 (1.2) Prostate 39 (3.3) 
HIV positive women (n = 1237) HIV negative women (n = 2406) 
Cervix 448 (36.2) Breast 874 (36.3) 
Breast 241 (19.5) Cervix 718 (29.8) 
Kaposi sarcoma 226 (18.3) Oesophagus 93 (3.9) 
NHL 95 (7.7) Ovary 89 (3.7) 
Diffuse large B cell lymphoma 61 (4.9)   
Burkitt’s lymphoma 9 (0.7) 
Other NHL 25 (2.0) 
Lip, oral cavity and pharynx 26 (2.1) Uterus 84 (3.5) 
Vulva 22 (1.8) Colon 54 (2.2) 
Uterus 17 (1.4) Lip, oral cavity and pharynx 51 (2.1) 
Conjunctiva, Eye 17 (1.4) Lung 48 (2.0) 
Lung 15 (1.2) Anorectal 39 (1.6) 
Oesophagus 14 (1.1) NHL 30 (1.3) 
  Diffuse large B cell lymphoma 10 (0.4) 
Burkitt’s lymphoma 2 (0.1) 
Other NHL 18 (0.8) 
Numbers (%) are shown. 
*non-squamous cell carcinoma. 
HIV testing and prevalence in cancer patients 
Among patients with available results, 1833 had a positive ELISA test, for a prevalence of 
HIV infection of 33.7% (95% CI 32.5-35.0). Out of the 1833 cancer patients with a positive 
HIV-1 test, 626 [34% (95% CI 32.0 – 36.3)] were unaware of their positive HIV status. The 
overall prevalence of previously undiagnosed HIV among all black cancer patients was 
11.5% (95% CI 10.7-12.4): 626 patients out of 5436 patients with HIV test results. Among 
the 3603 patients who tested HIV-1 negative, 1588 (44%) were unaware of their HIV status. 
Figure 2 and Figure 3 compare the age-specific HIV prevalence in black men and women 
with cancer to black men and women in the general South African population [19]. In men 
with KS or NHL age-specific HIV prevalence was high ranging from 96.3% to 100% for KS 
and 33.3% to 100% for NHL, in the age groups 20 to 60 years. In men with other cancers 
HIV prevalence was generally slightly higher in black cancer patients than in the black male 
population. HIV prevalence in black men with other cancers rose with age, peaking in the 
35–39 years age group and then declining to below 10% in men 60 years or older. In women 
the pattern was similar to that observed in men for KS, NHL and for other cancers. The 
pattern differed for cervical cancer: HIV prevalence was 100% in women aged 20–24 years 
and steadily declined with increasing age to 10% in women aged 60 or older (Figure 3). 
Figure 2 HIV prevalence in male cancer patients (2004 – 2009). Age-specific HIV 
prevalence in male cancer patients in the present study compared with age-specific HIV 
prevalence in black men in South Africa as reported in the 2008 National HIV Prevalence 
Survey. 
Figure 3 HIV prevalence in female cancer patients (2004 – 2009). Age-specific HIV 
prevalence in female cancer patients in the present study compared with age-specific HIV 
prevalence in black women in South Africa as reported in the 2008 National HIV Prevalence 
Survey. 
Factors associated with prior HIV testing 
A total of 4092 (75%) out of 5436 patients had ever been tested for HIV; of those, 1303 
(32%) had been tested before their current cancer illness. The remaining 2789 (68%) had 
been tested for HIV at the time of their cancer illness or diagnosis. The median time elapsed 
since the last HIV test at time of interview was 1.9 months (IQR 1.0 – 5.6). Only 19 (<1%) 
out of the 4092, who had ever been tested, were unwilling to disclose the results of their 
previous HIV test. Factors independently associated with prior HIV testing in men included 
younger age, urban residence, higher level of education and more recent year of interview 
(Table 3). For example, men with secondary/tertiary education had a 1.79 times greater odds 
of a prior HIV test than men with no education. Similarly, in women, younger age, higher 
level of education and more recent year of interview were associated with prior testing. In 
addition, having children under the age of five and hormonal contraceptive use were 
independently associated with prior HIV testing (Table 4). 
Table 3 Factors associated with HIV testing in black South African men with cancer (2004 – 2009) 
Factor No previous HIV test Previous HIV test Crude logistic model Multivariate logistic model 
N (%) N (%) OR (95% CI) OR (95% CI) 
Age     
≤49 years 641 (45.8) 238 (60.7) 1 1 
>49 years 760 (54.2) 154 (39.3) 0.54 (0.43 – 0.68) 0.49 (0.39 – 0.63) 
Place of residence     
Urban 1241 (88.6) 367 (93.6) 1 1 
Rural 160 (11.4) 25 (6.4) 0.53 (0.34 – 0.82) 0.61 (0.39 – 0.97) 
Marital status     
Married/living together 960 (68.6) 249 (63.7) 1  
Single/never married 170 (12.2) 48 (12.3) 1.09 (0.77 – 1.54)  
Widowed 99 (7.1) 36 (9.2) 1.40 (0.93 – 2.10)  
Separated/divorced 170 (12.2) 58 (14.8) 1.32 (0.95 – 1.83)  
Year of interview     
2004-2005 197 (14.1) 30 (7.7) 1 1 
2006 235 (16.8) 38 (9.7) 1.06 (0.63 – 1.78) 1.04 (0.61 – 1.76) 
2007 351 (25.1) 77 (19.6) 1.44 (0.91 – 2.27) 1.88 (1.17 – 3.02) 
2008 355 (25.3) 107 (27.3) 1.98 (1.27 – 3.07) 2.44 (1.54 – 3.85) 
2009 263 (18.8) 140 (35.7) 3.49 (2.26 – 5.40) 4.13 (2.62 – 6.52) 
Level of education     
None 145 (10.4) 24 (6.1) 1 1 
Primary 495 (35.4) 94 (24.0) 1.15 (0.71 – 1.86) 1.14 (0.69 – 1.89) 
Secondary/tertiary 758 (54.2) 274 (69.9) 2.18 (1.39 – 3.44) 1.79(1.11 – 2.90) 
Alcohol use     
Non-drinkers 397 (28.3) 118 (30.1) 1  
Moderate drinkers 635 (45.3) 165 (42.1) 0.87 (0.67 – 1.14)  
Heavy/binge drinkers 369 (26.3) 109 (27.8) 0.99 (0.74 – 1.34)  
Smoking     
Non-smokers 318 (22.7) 100 (25.5) 1  
Ex-smokers 221 (15.8) 52 (13.3) 0.75 (0.51 – 1.09)  
Current smokers (1-14 g/day) 580 (41.4) 155 (39.5) 0.85 (0.64 – 1.13)  
Current smokers (15+ g/day) 282 (20.1) 85 (21.7) 0.96 (0.69 – 1.33)  
Lifetime number of sexual partners     
0-1 89 (6.5) 21 (5.5) 1  
2-5 633 (46.3) 156 (41.2) 1.04 (0.63 – 1.73)  
6+ 645 (47.2) 202 (53.3) 1.33 (0.80 – 2.19)  
Having children under 5 years     
No 828 (79.8) 228 (75.2) 1  
Yes 210 (20.2) 75 (24.8) 1.30 (0.96 – 1.75)  
Cancer type     
AIDS-defining 294 (21.0) 104 (26.5) 1  
Other cancers 1107 (79.0) 288 (73.5) 0.73(0.57 – 0.95)  
Interviewer     
Interviewer 1 771 (55.0) 291 (74.2) 1 1 
Interviewers 2 and 3 630 (45.0) 101 (25.8) 0.69 (0.63 – 0.76) 0.43 (0.33 – 0.56) 
Table 4 Factors associated with HIV testing in black South African women with cancer 
Factor No previous HIV test N (%) Previous HIV test N (%) Crude logistic model OR (95% CI) Multivariate logistic model OR (95% CI) 
Age     
≤49 years 1368 (50.1) 707 (77.6) 1 1 
>49 years 1364 (49.9) 204 (22.4) 0.29 (0.24 – 0.34) 0.33 (0.27 – 0.41) 
Place of residence     
Urban 2392 (87.7) 840 (92.3) 1  
Rural 336 (12.3) 70 (7.7) 0.59 (0.45 – 0.78)  
Marital status     
Married/living together 1503 (55.1) 435 (47.9) 1  
Single/never married 280 (10.3) 182 (20.0) 2.24 (1.81 – 2.78)  
Widowed 483 (17.7) 119 (13.1) 0.85 (0.68 – 1.07)  
Separated/divorced 462 (16.9) 173 (19.0) 1.29 (1.05 – 1.59)  
Year of interview     
2004-2005 497 (18.2) 77 (8.5) 1 1 
2006 433 (15.8) 99 (10.9) 1.47 (1.07 – 2.04) 1.61 (1.14 – 2.28) 
2007 642 (23.5) 173 (19.0) 1.74 (1.30 – 2.33) 2.91 (2.10 – 4.01) 
2008 648 (23.7) 231 (25.4) 2.30 (1.73 – 3.05) 3.62 (2.65 – 4.95) 
2009 512 (18.7) 331 (36.3) 4.17 (3.16 – 5.50) 6.04 (4.45 – 8.21) 
Level of education     
None 336 (12.3) 44 (4.8) 1 1 
Primary 880 (32.3) 172 (18.9) 1.49 (1.04 – 2.13) 1.26 (0.86 – 1.84) 
Secondary/tertiary 1511 (55.4) 695 (76.3) 3.51 (2.53 – 4.87) 2.08 (1.45 – 2.97) 
Alcohol use     
Non-drinkers 2071 (75.8) 667 (73.2) 1  
Moderate drinkers 401 (14.7) 141 (15.5) 1.09 (0.88 – 1.35)  
Heavy/binge drinkers 260 (9.5) 103 (11.3) 1.23 (0.96 – 1.57)  
Smoking     
Non-smokers 2240 (82.0) 778 (85.4) 1  
Ex-smokers 152 (5.6) 32 (3.5) 0.61 (0.41 – 1.90)  
Current smokers (1–14 
g/day) 
278 (10.2) 86 (9.4) 0.89 (0.69 – 1.15)  
Current smokers (15+ 
g/day) 
62 (2.3) 15 (1.6) 0.70 (0.39 – 1.23)  
Lifetime number of 
sexual partners 
    
0-1 383 (14.3) 92 (10.3) 1.38 (1.08 – 1.76)  
2-5 1962 (73.0) 650 (72.5) 1.87 (1.39 – 2.52)  
6+ 342 (12.7) 154 (17.2)   
Having children under 5 
years 
  1 1 
No 2497 (92.8) 680 (75.5) 4.18 (3.39 – 5.16) 2.59 (2.04 – 3.29) 
Yes 194 (7.2) 221 (24.5)   
Cancer type     
AIDS-defining 1140 (41.7) 385 (42.3) 1  
Other 1592 (58.3) 526 (57.7) 0.98 (0.84 – 1.14)  
Hormonal contraceptive 
use 
    
Never 1105 (40.6) 224 (24.7) 1 1 
Ever 1615 (59.4) 684 (75.3) 2.09 (1.76 – 2.47) 1.33 (1.09 – 1.62) 
Interviewer     
Interviewer 1 1426 (52.2) 673 (73.9) 1 1 
Interviewers 2 and 3 1306 (47.8) 238 (26.1) 0.74 (0.69 – 0.78) 0.36 (0.30 – 0.44) 
Discussion 
The prevalence of HIV infection in black cancer patients diagnosed in a large tertiary 
academic hospital in Johannesburg, South Africa was 34%, demonstrating a higher HIV 
prevalence in black cancer patients than in the general black population. While three-quarters 
of all patients had ever been tested for HIV, about a third of the infected patients were 
unaware of their HIV infection. Overall more than 10% of all newly diagnosed black cancer 
patients had a previously unknown HIV infection. The HIV prevalence in this population was 
substantially higher than the national South African adult HIV prevalence of 18% [19] but 
comparable with other high risk groups. For example, the National Antenatal Sentinel HIV 
and Syphilis Prevalence survey showed that 29% of pregnant women were HIV positive in 
2009 [22]. HIV prevalence in cancer patients is expected to be high since HIV is a well-
established risk factor for AIDS-defining cancers, but the prevalence was also higher in 
patients with cancers that are not classified as AIDS-defining. Overall HIV prevalence in 
cancer patients in a previous JCCCS publication covering the period March 1995 – June 
2004, was found to be 10% [16]. The current analysis, covering the period November 2004 - 
December 2009 found a much higher prevalence of 34%. The difference in the HIV sero-
positivity reflects the different stages of the South African HIV epidemic in the two time 
periods. The much lower HIV prevalence in 1990s might have affected overall HIV 
prevalence in previous JCCCS publications exemplified by an antenatal HIV prevalence of 
10.4% in 1995 which steadily rose to 29.5% in 2004, plateauing around this level in the years 
2004 to 2012 [23]. 
We found that younger age, higher level of education and more recent year of interview were 
associated with having been tested for HIV both in men and in women. Older men and 
women were less likely to have been tested; this is consistent with a study of age and gender 
differences in HIV testing uptake done in South Africa’s Mpumalanga province [11]. In 
Mpumalanga the peak age-group for HIV testing was 20–39 years for both men and women; 
older men and women were less likely to get tested and a significant proportion of older 
people who did test did so only after medical referral [11]. Black cancer patients interviewed 
in more recent years had a higher odds of prior HIV testing and, similarly, there was an 
increase in HIV testing in the Mpumalanga study from 2002 to 2006 [11]. Greater availability 
of HIV testing facilities and of antiretroviral treatment could partially explain improved 
testing coverage in recent years. As expected, higher level of education was associated with 
greater prevalence of prior HIV testing in both men and women [14,24]. Indeed, the 
determinants of HIV testing in black men and women with cancer are similar to those seen in 
the general South African population [10,11,14,15]. 
Women having children under the age of five or using hormonal contraceptives were also 
more likely to have been tested for HIV. Younger women who use hormonal contraception 
and who have small children would have attended health facilities where they will have been 
offered HIV testing [15]. Routine opt-out antenatal HIV testing in pregnant women has been 
part of the prevention of mother-to-child transmission of HIV (PMTCT) programme since 
2001 [25], which probably explains the higher HIV testing prevalence in women with young 
children. This finding underscores the potential of implementation of PITC when patients 
with cancer and HIV co-morbidity can be identified thereby allowing for appropriate 
treatment and referral for HIV care. 
Men and women with KS had a persistently high HIV prevalence across the age-groups, 
whereas for cervical cancer the prevalence was highest in young women and declined 
steadily with increasing age. This is consistent with the young age at cervical cancer 
diagnosis as previously described in HIV positive women in South Africa [26], and supports 
the hypothesis that HIV works as a cofactor which shortens the pre-invasive stage in cervical 
carcinogenesis [26]. The leading cancers in men and women differed by HIV status, with 
AIDS-defining cancers accounting for 59% and 62% of all cancers in HIV positive men and 
women respectively. The non-AIDS defining cancers Hodgkin lymphoma and skin (non-
melanoma, non-squamous cell carcinoma) in men, and vulval and conjunctival cancers in 
women emerged in the top ten. The association of these non-AIDS defining cancers with HIV 
has been described before in the JCCCS [16] and in other African settings [27-30]. Anal 
cancer is the most common non-AIDS defining cancer in HIV positive men in Europe and the 
United States [31]. The conspicuous absence of anorectal cancers in the top ten cancers in 
HIV positive black men in our study can be explained by the predominantly heterosexual 
transmission of HIV in South Africa [32]. Conjunctival cancer was detected among the top 
ten cancers in HIV positive female black cancer patients but was not in the top ten cancers in 
HIV positive men. This might reflect differences in health seeking behaviours between men 
and women, hindering diagnosis in men. Also, it might possibly reflect an HIV-related shift 
from the male predominance of conjunctival cancer to a female predominance as previously 
observed in a study of conjunctival cancer in Zimbabwe, where 70% of conjunctival cancers 
were in women [33]. 
The overall undiagnosed HIV prevalence of 11.5% is comparable to other studies done in the 
general population; the prevalence of previously undiagnosed HIV was 10.3% in a 
population-based sero-survey done in Cape Town [13]. In the current study, over a third of 
HIV positive cancer patients were unaware of their HIV status. This is concerning and has 
implications for management of cancer patients. Undiagnosed HIV infection could 
potentially worsen treatment outcomes for cancer patients, who might have untreated HIV-
related immunodeficiency in addition to coping with cancer-specific chemotherapy, radiation 
therapy or surgery. Further research is required to understand why newly diagnosed cancer 
patients are not routinely tested for HIV or are unaware of their HIV result. 
Our analysis has some limitations. In the first 2 years (November 2004 – November 2006) of 
introduction of the HIV section of the questionnaire, it was only used for patients aged 55 or 
less; thereafter it was used for all patients. Patients not interviewed on HIV testing were 
therefore older, and had a lower HIV prevalence than those interviewed (see Additional file 
1: Table S5). This might have inflated overall HIV prevalence in the study. Furthermore, 
there was potential for recall bias and differential reporting of previous HIV testing in 
patients who had and had not previously tested positive for HIV. Although interviews were 
conducted by experienced nurse counsellors there was possible social desirability bias, as 
patients might want to give health care workers responses which cast them favourably. Self-
reported HIV status may overestimate true lack of awareness of HIV status where patients 
who are aware of their HIV positive status may report unknown or HIV negative status [34]. 
Hence HIV stigma might have affected the high prevalence of undiagnosed HIV. The study 
was limited to black cancer patients who were mainly from southern Gauteng province; thus 
the results may not apply to other provinces in South Africa or other countries in sub-Saharan 
Africa. This study was conducted during the period 2004–2009; since then there has been 
continued ART scale-up, and in 2010, national HIV testing guidelines were published and a 
national HIV testing campaign was implemented [6,35]. Therefore current HIV testing 
patterns and HIV burden in cancer patients might differ from the findings of this study. HIV 
testing patterns in cancer patients in South Africa had not previously been studied. The 
current analysis provides a baseline picture of HIV testing patterns in cancer patients in the 
first five years of the roll-out of antiretroviral combination therapy in South Africa. Another 
strength is the large sample size, which allowed for precise estimates. The majority of 
patients had independent study related HIV test results and most other variables were fairly 
complete. 
Conclusions 
HIV prevalence is higher in black cancer patients in Johannesburg than in the general black 
population, even among patients with cancers which are not AIDS defining. Clinicians should 
not miss the opportunity to offer PITC to cancer patients at the time of cancer diagnosis. The 
HIV testing patterns in black cancer patients reflect targeted HIV testing in the reproductive 
age group. More than a third of newly diagnosed black cancer patients with HIV were 
unaware of their HIV status. This emphasises the need for implementation of PITC not only 
in the general population, but also in black cancer patients in South Africa’s high HIV 
prevalence setting. Routine opt-out HIV testing in black cancer patients should be 
implemented as standard of care in South Africa. 
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